ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Forest, TransTech In Diabetes Drug Pact

by Lisa M. Jarvis
June 14, 2010 | APPEARED IN VOLUME 88, ISSUE 24

Forest Laboratories will pay $50 million for access to TransTech Pharma’s gluco­kinase activator compounds, which are in early-phase studies for the treatment of type 2 diabetes. TransTech could earn up to $1.1 billion in milestone payments as the compounds progress toward commercialization. TransTech developed the glucokinase activators in collaboration with Novo Nordisk, which returned the compounds to the biotech firm in 2007 after deciding to exit small-molecule research. Glucokinase is active in the pancreas and liver, but TransTech’s compounds specifically modulate the enzyme’s role in glucose metabolism in the liver.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment